B7-H3 CAR-NK cells

B7-H3 CAR-NK cells are an investigational cell-based immunotherapy consisting of natural killer (NK) cells genetically engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (also known as CD276). B7-H3 is a transmembrane immune checkpoint molecule that is frequently overexpressed on the surface of various malignant cells, including those in glioblastoma, non-small cell lung cancer, and pediatric solid tumors, while maintaining limited expression in normal tissues. These CAR-NK cells can be derived from multiple sources, such as umbilical cord blood, NK-92 cell lines, or induced pluripotent stem cells (iPSCs). As an allogeneic "off-the-shelf" therapy, B7-H3 CAR-NK cells offer potential safety advantages over CAR-T cells, including a reduced risk of graft-versus-host disease (GvHD) and a more favorable cytokine release profile. Research is being conducted by various institutions, including Osaka University and Fate Therapeutics (developing the iPSC-derived candidate FT573), to evaluate their efficacy against refractory solid tumors and brain cancers.

Other names

CD276 CAR-NK cellsCD-276 CAR-NK cellsCD 276 CAR-NK cellsB7-H3-targeted CAR-NK cellsB-7-H3-targeted CAR-NK cellsB 7-H3-targeted CAR-NK cellsanti-B7-H3 CAR-NK cellsanti-B-7-H3 CAR-NK cellsanti-B 7-H3 CAR-NK cells